What's actually happening at Mounjaro week 7?

Which dose are most people on by week 7?

Mounjaro's licensed schedule starts at 2.5mg for the first four weeks. That opening dose is a settling-in period, its job is to let your body adjust to tirzepatide before the prescriber moves you up. The 5mg pen usually follows at week five, which means that by week seven most people on a standard titration are partway through that second strength.

That matters because 5mg is where many people notice the medicine shifting from background presence to something more active. Appetite drops feel less sudden and more like a new normal. Gastric emptying continues to slow, meals feel satisfying with less food, and the dual GIP and GLP-1 mechanism (described in detail on the tirzepatide overview page) is working across both gut-hormone pathways. The full week-by-week guide maps how this builds through the treatment schedule if you want the broader picture.

A small number of people remain on 2.5mg for longer, their prescriber may decide to hold the dose if side effects have been pronounced. Neither pace is wrong. Titration timing is a clinical judgement, not a race.

Are side effects still normal at week 7?

Yes, and for many people they're noticeably lighter than they were in the first few weeks. The most common effects with Mounjaro are gastrointestinal: nausea, loose stools, constipation, bloating, and burping. These typically peak around a dose increase and settle within days to a couple of weeks as the body adapts. By week 7 on 5mg, that adaptation is usually well underway.

Fatigue and mild headache can also linger but are less frequently reported at this stage. Injection-site redness or mild irritation remains possible, rotating between the abdomen, thigh and upper arm helps reduce it, as the Mounjaro guide covers in more detail.

The side effects to take seriously at any point in treatment are outlined by the NHS tirzepatide medicines page: severe, persistent stomach pain that radiates to the back warrants urgent medical attention as it can indicate pancreatitis. Gallbladder symptoms, signs of dehydration from prolonged vomiting or diarrhoea, or any allergic reaction also require prompt care. Report anything unexpected to your prescriber, and serious or unusual reactions can be flagged through the MHRA Yellow Card scheme.

If side effects at week 7 feel worse than they did a fortnight ago, that's worth raising. It can happen (stress, illness, a change in eating pattern) but your prescriber should know.

Why might progress feel slower this week?

Weight loss on Mounjaro is rarely a straight downward line. People who've looked at the eight-week weight loss patterns often describe a step-change shape: a period of faster change followed by a brief plateau, then movement again. Week 7 sits squarely in the territory where that first plateau often appears.

A few things contribute. Water retention can mask fat loss on the scales. The body adapts its energy expenditure to some degree as weight drops. And appetite suppression, however consistent it feels now compared to the very first week, doesn't eliminate every urge to eat more than your body currently needs. Protein intake, sleep quality and activity levels all influence the rate of change without changing whether the medicine is working.

The SURMOUNT-1 trial, published in the New England Journal of Medicine, found average body-weight reductions of around 20–21% at the 15mg dose over 72 weeks, but that's a long-horizon figure across thousands of participants, not a week-by-week promise. A quiet week 7 is part of the same arc.

If you're wondering whether your week 5 and 6 pattern fits with what most people experience, the week 5 and week 6 pages cover those windows in the same detail.

What should you be thinking about as week 8 approaches?

The next decision point is usually around week 8 to 9: does the prescriber continue at 5mg or move to 7.5mg? That depends on how well 5mg is being tolerated, what progress looks like, and clinical judgement. It's not automatic, evidence of how the current dose is landing matters, which is why keeping a rough note of weight, appetite and any symptoms is genuinely useful rather than just busywork.

Cost and logistics are also worth thinking about at this stage. Many people begin to understand the longer-term financial picture around weeks 7 to 8 once the initial focus on side effects passes. The context behind Mounjaro pricing in the UK explains how and why costs changed from September 2025, which affects what you'll pay at any dose going forward.

At nume, every repeat order goes through a clinical review before it's processed, your case is read by a real prescriber, not passed through a checklist automatically. If week 7 has raised questions, starting a conversation with our prescribers is the place to do it. There's no obligation and no hurry.